Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$9.72
-$0.10(-1.19%)
At close: 4:00 PM EDT
$9.72
-$0.10(-1.19%)
Day’s Range― - ―
52-Week Range$7.21 - $20.46
Previous CloseN/A
Volume2.34M
Average Volume (3M)3.09M
Market Cap
$2.39B
Enterprise Value$2.00B
Total Cash (Recent Filing)$136.02M
Total Debt (Recent Filing)$203.84M
Price to Earnings (P/E)14.8
Beta0.82
Next Earnings
Nov 11, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding223,984,680
10 Day Avg. Volume2,950,837
30 Day Avg. Volume3,092,418
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit6.02
Enterprise Value/Ebitda8.57
Forecast
1Y Price Target
$15.00Price Target Upside54.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.79
Revenue Forecast (FY)$535.35M
Bulls Say, Bears Say
Bulls Say
ASCENIV Adoption GrowthASCENIV is showing sustained commercial traction through broader physician adoption, new patient starts and increasing utilization. Continued uptake can support durable revenue growth and partially offset weakness in legacy products, while strengthening the company’s position in its target immunoglobulin market.
Profitability And Cash GenerationExpanding gross margins, higher EBITDA and strong free cash flow indicate that ADMA is converting revenue growth into meaningful earnings and liquidity. This improves capacity to fund operations, development and commercial investment internally, while reducing reliance on external financing.
Manufacturing And Plasma IntegrationEmbedded yield-enhanced manufacturing and diversified plasma sourcing support product availability, production efficiency and margin performance. These operating capabilities can create a more durable platform for scaling plasma-derived therapies and reduce vulnerability to interruptions in raw-material access.
Bears Say
BIVIGAM DeclineThe expected BIVIGAM contraction creates a material revenue gap that ASCENIV must replace. This raises execution risk because the company’s growth outlook depends on successfully shifting demand toward ASCENIV while managing the operational and commercial effects of a declining legacy product.
Standard IG Pricing PressurePersistent industry supply and pricing pressure can limit recovery in standard immunoglobulin volumes and prices, directly challenging revenue quality and margin sustainability. Continued discounting may also constrain the benefits of operational improvements across the portfolio.
Working-capital IntensityElevated inventory and receivables require substantial capital to support growth and increase the importance of accurate demand planning and collections. If inventory conversion or customer payments weaken, cash generation could fall and operating flexibility could narrow despite reported profitability.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $2.39B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Aug 05, 2026. The company reported $0.165 earnings per share for the quarter, beating the consensus estimate of $0.163 by $0.002.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.2.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 223,984,680 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.165 in its last earnings report, beating expectations of $0.163. Following the earnings report the stock price went up 8.639%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (54.32% Upside)
$15.00 (54.32% Upside)
Blogger Sentiment
Neutral
ADMA Sentiment 50%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.64%
12-Months-Change
Fundamentals
Return on Equity
39.59%
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ADMA Biologics
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial story driven by strong ASCENIV revenue growth (+24% YoY), meaningful margin expansion (gross margin up to 69% from 55%), improved adjusted EBITDA (+22% YoY), solid cash generation and a healthy balance sheet with active share repurchases. Offsetting risks discussed include a significant decline in legacy BIVIGAM volumes (management expects ~40%–50% decline vs 2025), ongoing competitive pricing pressure in the standard IG market, elevated working capital (inventory and receivables) and a higher effective tax rate. Management reiterated full-year guidance and highlighted clinical evidence and pipeline progress (SG-001), supporting confidence in the company’s growth trajectory despite near-term market headwinds.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$15.00
▲(54.32% Upside)
Technical Analysis
Ownership Overview
3.54% Insiders
26.79% Mutual Funds
0.04% Other Institutional Investors
37.38% Public Companies and
Individual Investors